Futura Medical Plc came under significant selling pressure during Thursday's trading session as investors reduced exposure to higher-risk healthcare growth companies.
Futura Medical plc attracted increased investor attention after its shares advanced5.00%during trading on16 July 2026.
Genedrive plc attracted renewed buying interest after its shares climbed4.76%during trading on16 July 2026.
Oxford BioDynamics came under renewed selling pressure during Thursday's session as investors continued evaluating the company's financial position following its recently published interim results.
• ABDX shares gained 2.56% on 16 July 2026, closing at 10.00 GBX.• Abingdon Health plc has a market capitalization of approximately 24.64 million GBP, placing it in the micro-cap segment.• The company develops and manufactures rapid diagnostic testing technologies, including lateral flow solutions.• …
• COG shares gained 4.71% on 16 July 2026, closing at 32.99 GBX.• Cambridge Cognition Holdings Plc has a market capitalization of approximately 17.02 million GBP, placing it in the micro-cap segment.• The company develops digital cognitive assessment technologies used in clinical trials and …
• IMM shares gained 5.11% on 16 July 2026, closing at 3.89 GBX.• ImmuPharma PLC has a market capitalization of approximately 23.08 million GBP, placing it in the micro-cap segment.• The company develops therapeutic candidates focused on autoimmune and inflammatory diseases.• Clinical development, regulatory …
AstraZeneca has built out a wide oncology portfolio — antibody-drug conjugates and targeted therapies developed alone and with partners — alongside respiratory, cardiovascular and rare-disease franchises strengthened by the Alexion acquisition. FY2025 results, published February 2026, highlighted a run of positive late-stage trial readouts …
PureTech identifies scientific advances, builds development programmes around them, and either advances them in-house or seeds them into separately capitalised 'Founded Entities.' The signature success remains Karuna Therapeutics — Bristol Myers Squibb completed its $14bn acquisition of Karuna in March 2024, and the underlying …
Three activities: contract design and manufacture of implantable and long-term medical devices through RUA Medical (roughly 86% of group revenue); licensing of proprietary Elast-Eon biostable polyurethane through RUA Biomaterials; and development of its own implantable technologies, principally structural heart and vascular. Following the September …